|
|
| | PROTAC BTK Degrader-6 Basic information |
| Product Name: | PROTAC BTK Degrader-6 | | Synonyms: | PROTAC BTK Degrader-6;1H-Isoindole-1,3(2H)-dione, 5-[3-[[4-[2-[4-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-oxoethyl]-1-piperazinyl]methyl]-1-azetidinyl]-2-(2,6-dioxo-3-piperidinyl)- | | CAS: | 2767204-39-5 | | MF: | C45H47N11O6 | | MW: | 837.93 | | EINECS: | | | Product Categories: | | | Mol File: | 2767204-39-5.mol |  |
| | PROTAC BTK Degrader-6 Chemical Properties |
| density | 1.545±0.14 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | pka | 10.832±0.40(predicted) |
| | PROTAC BTK Degrader-6 Usage And Synthesis |
| Uses | PROTAC BTK Degrader-6 (Compound 15) is a PROTAC BTK degrader (DC50: 3.18 nM. PROTAC BTK Degrader-6 has anti-inflammatory activity, inhibits NF-κB activation, and inhibits the expression of pro-inflammatory cytokines (e.g. IL-1β, IL-6)[1]. | | References | [1] Huang J, et al. Discovery of Ibrutinib-based BTK PROTACs with in vivo anti-inflammatory efficacy by inhibiting NF-κB activation. Eur J Med Chem. 2023 Jul 18;259:115664. DOI:10.1016/j.ejmech.2023.115664 |
| | PROTAC BTK Degrader-6 Preparation Products And Raw materials |
|